Clin-nov Medical Executive and Leadership Team

Rui Yang, the Chief Executive Officer at Clin-nov Medical, directs the overarching strategic vision for the organization. By aligning research capabilities with the evolving needs of the pharmaceutical industry, the Chief Executive Officer ensures that Clin-nov Medical maintains a competitive edge in drug development. Rui Yang oversees the integration of advanced scientific methodologies across all service lines, fostering a culture of excellence and precision. This leadership role involves constant engagement with the Board to secure long-term growth and market expansion. By prioritizing high-impact research outcomes, the Chief Executive Officer drives the company toward achieving its mission of delivering innovative treatments to patients globally. Through rigorous oversight of corporate governance and resource allocation, the Chief Executive Officer strengthens the operational foundation of the firm. Ultimately, the Chief Executive Officer secures the future of the organization by championing scientific integrity and operational efficiency in every project.

Da Zhang, the Chief Financial Officer at Clin-nov Medical, manages the fiscal health and capital allocation strategies of the organization. Overseeing financial planning, budgeting, and risk management, the Chief Financial Officer ensures that the company maintains the necessary resources to support large-scale drug research initiatives. Da Zhang monitors revenue streams and cost structures to optimize profitability while maintaining the high quality of service expected by pharmaceutical clients. This leadership role involves close coordination with the executive team to evaluate investment opportunities in new research technologies and market expansion. By providing transparent financial reporting and strategic insights, the Chief Financial Officer enables informed decision-making across the firm. Through the implementation of rigorous financial controls, the Chief Financial Officer safeguards the long-term stability of the business. Ultimately, Da Zhang drives sustainable growth by aligning financial performance with the core mission of advancing medical science and patient care.

Qi Yin, the Chief Operating Officer & Head Chief Strategy Officer (US) at Clin-nov Medical, directs the daily operations and strategic initiatives within the North American market. Overseeing the execution of clinical research projects, the Chief Operating Officer & Head Chief Strategy Officer (US) ensures that all operational workflows adhere to strict regulatory and quality standards. Qi Yin manages the cross-functional teams responsible for delivering comprehensive drug development solutions to clients. This leadership role involves refining internal processes to improve project turnaround times and operational efficiency. By developing and implementing regional growth strategies, the Chief Operating Officer & Head Chief Strategy Officer (US) strengthens the presence of the company in the competitive pharmaceutical landscape. Through the coordination of resources and talent, the Chief Operating Officer & Head Chief Strategy Officer (US) supports the achievement of corporate objectives. Ultimately, Qi Yin drives operational excellence by ensuring that every project meets the highest standards of scientific rigor and client satisfaction.

Ruiling Peng, the Chief Technology Officer at Clin-nov Medical, architects the digital and scientific infrastructure necessary for complex drug research. Overseeing the implementation of cutting-edge laboratory technologies, the Chief Technology Officer ensures that all research processes meet the highest standards of accuracy and efficiency. Ruiling Peng manages the technical teams responsible for data analysis and clinical trial support, facilitating seamless integration between research platforms and client requirements. This leadership role requires constant collaboration with the Chief Executive Officer to align technological investments with the broader corporate strategy. By optimizing internal workflows and adopting emerging research tools, the Chief Technology Officer enhances the overall productivity of the organization. Through the deployment of scalable technology solutions, the Chief Technology Officer supports the expansion of research capabilities across international markets. Ultimately, the Chief Technology Officer drives innovation by maintaining a robust and secure technological environment for all pharmaceutical development projects.

Xinhui Hu, the Chief Technology Officer, Cbo at Clin-nov Medical, bridges the gap between technical research capabilities and business development objectives. Overseeing the commercialization of proprietary research technologies, the Chief Technology Officer, Cbo ensures that the company effectively communicates its scientific value proposition to potential pharmaceutical partners. Xinhui Hu manages the strategic partnerships that drive revenue growth and expand the market reach of the organization. This leadership role requires balancing the technical requirements of drug development with the commercial goals of the firm. By identifying new business opportunities and fostering client relationships, the Chief Technology Officer, Cbo enhances the market position of the company. Through the integration of market intelligence into the research pipeline, the Chief Technology Officer, Cbo ensures that the services offered remain relevant and highly sought after. Ultimately, the Chief Technology Officer, Cbo secures the commercial success of the organization by aligning technical innovation with market demand.